Prostin VR Pediatric
FDA Approves TOBI Podhaler for Bacterial Lung Infection in Cystic Fibrosis Patients »
"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
Prostin VR Pediatric
Prostin VR Pediatric®
(alprostadil) Injection, USP
500 micrograms per mL
WARNING
Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC (alprostadil) Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC (alprostadil) should be used where ventilatory assistance is immediately available.
DRUG DESCRIPTION
PROSTIN VR PEDIATRIC (alprostadil) Sterile Solution for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1.0 ml dehydrated alcohol.
The chemical name for alprostadil is (11α, 13E, 15S)-11, 15 dihydroxy -9- oxoprost-13-en-1-oic acid, and the molecular weight is 354.49.
Alprostadil is a white to off-white crystalline powder with a melting point between 110° and 116° C. Its solubility at 35°C is 8000 micrograms per 100 ml double distilled water.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Prostin VR Pediatric Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
